378 related articles for article (PubMed ID: 35623069)
1. The current management and biomarkers of immunotherapy in advanced gastric cancer.
Chang X; Ge X; Zhang Y; Xue X
Medicine (Baltimore); 2022 May; 101(21):e29304. PubMed ID: 35623069
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway.
Cheng R; Li B; Wang H; Zeng Y
Clin Transl Oncol; 2023 Nov; 25(11):3122-3138. PubMed ID: 37036597
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
5. Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer.
Kang BW; Chau I
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817133
[TBL] [Abstract][Full Text] [Related]
6. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
Masetti M; Lindinger M; Lorenzen S
Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Gastric Cancer.
Högner A; Moehler M
Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
[TBL] [Abstract][Full Text] [Related]
11. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
[TBL] [Abstract][Full Text] [Related]
12. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
[TBL] [Abstract][Full Text] [Related]
13. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis.
Roviello G; Corona SP; D'Angelo A; Rosellini P; Nobili S; Mini E
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936762
[TBL] [Abstract][Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
16. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
17. Current status of immune checkpoint inhibitors for gastric cancer.
Kono K; Nakajima S; Mimura K
Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
[TBL] [Abstract][Full Text] [Related]
19. Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients.
Chen X; Zhang H; Wang M; Liu H; Hu Y; Lin T; Chen H; Zhao M; Chen T; Li G; Yu J; Zhao L
Front Immunol; 2022; 13():783695. PubMed ID: 35401534
[TBL] [Abstract][Full Text] [Related]
20. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
